Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Agarwal's Eye Hospital reported strong FY26 results with revenue from operations growing 18.6% YoY to ₹470.87 crore from ₹397.15 crore. Net profit after tax rose 28.3% to ₹70.10 crore versus ₹54.65 crore in the prior year. Q4 revenue stood at ₹120.01 crore with net profit of ₹16.24 crore. EBITDA for the full year was approximately ₹150.82 crore (31.5% margin), up from ₹123.09 crore (31% margin) in FY25. EPS improved to ₹147.02 per share from ₹116.28. The company recommended a final dividend of ₹4 per share, bringing total FY26 dividend to ₹7 per share (70%) including the ₹3 interim dividend already paid. Statutory auditors S.R. Batliboi & Associates issued an unmodified (clean) audit opinion. The Board also approved a scheme of amalgamation with holding company Dr. Agarwal's Health Care Limited, pending shareholder and regulatory approvals.
Strong financial performance with near 28% PAT growth and solid operating cash flows of ₹145 crore signals healthy business momentum. The 70% total dividend payout demonstrates shareholder-friendly policies. Clean audit opinion removes concerns about financial reporting quality, which is positive for investor confidence.